<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090194</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT IG03</org_study_id>
    <nct_id>NCT00090194</nct_id>
  </id_info>
  <brief_title>Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%</brief_title>
  <official_title>Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if IGIV-C, 10% will be effective in converting a
      donor-recipient crossmatch status from positive to negative. The crossmatch test is used to
      determine if the donor tissue and recipient tissue are compatible. The study will also
      evaluate if IGIV-C, 10% will allow successful kidney transplantation in a patient who
      otherwise would not be able to receive a transplant. Three dose levels of IGIV-C, 10% will be
      evaluated to determine what dose level is most effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney transplantation has emerged as the treatment of choice for patients with end-stage
      renal disease (ESRD). Preliminary data suggest that IGIV therapy could have significant
      benefits in modifying allograft rejection episodes, stabilizing long-term allograft function,
      and reducing ischemia/reperfusion injury.

      Qualified patients will have an in-vitro assessment of the ability of IGIV-C, 10% to convert
      the donor-specific crossmatch (cytotoxic assay) from positive to negative. Those patients
      with successful in-vitro conversion of the donor-specific crossmatch assay will be randomized
      to receive IGIV-C, 10% intravenously at a dose of either 2 gm/kg, 1 gm/kg, or 0.5 gm/kg.
      IGIV-C, 10% will be administered 3 to 5 days prior to planned transplantation and, if
      transplantation is successful, 7 days post-transplant. If after receiving the IGIV-C infusion
      the donor-specific crossmatch reveals that cell death has fallen to 20% or less above
      background, the crossmatch will be considered negative. If after receiving one infusion the
      crossmatch remains positive, additional IGIV-C infusions may be administered at one-month
      intervals, up to 4 infusions. A repeat crossmatch must be obtained after each infusion.
      Patients will be followed for 12 months post-transplant. Concomitant therapy will include a
      standard immunosuppression regimen of mycophenolate mofetil, tacrolimus, and prednisone
      following induction therapy with thymoglobulin.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monitoring of crossmatch conversion rate after one infusion of IGIV</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft survival and function</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average percentage panel reactive antibodies (PRA) reduction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>donor-specific unresponsiveness and allo-responsiveness in ESRD patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subject survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety endpoints, including incidence rates of infection, adverse events, and hospitalizations</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin Intravenous (Human), 10%</intervention_name>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Middle Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Recipient:

          -  End-stage renal disease

          -  No known contraindications for therapy with IGIV-C, 10%

          -  Have identified a living kidney donor

          -  Positive crossmatch with the intended donor

          -  Parent or guardian willing to provide consent, if applicable

        Exclusion Criteria for Recipient:

          -  Pregnant or breastfeeding

          -  Women of child-bearing age who are not willing or able to practice approved methods of
             contraception

          -  HIV infection

          -  Hepatitis B or hepatitis C infection

          -  History of positive tuberculin skin test

          -  Selective IgA deficiency, known anti-IgA antibodies, or history of severe allergy to
             any part of the clinical trial material

          -  Have received or will receive multiple organ transplants

          -  Any licensed or investigational live attenuated vaccine within 2 months of the
             screening visit

          -  Patients deemed unable to comply with the protocol

          -  Heart attack within 1 year of screening

          -  History of clinically significant thrombotic episodes or active peripheral vascular
             disease

          -  Investigational agents within 4 weeks of study entry

        Inclusion Criteria for Donor:

          -  Positive donor-specific crossmatch with the intended recipient

          -  ECOG performance status 0 or 1

          -  Excellent health

          -  Acceptable laboratory parameters

          -  Compatible blood type

          -  Normal heart and lung evaluations

          -  Parent or guardian willing to provide consent, if applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley C. Jordan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics, Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Good Samaritan Regional Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <reference>
    <citation>Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, Bromberg JS. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation. 2003 Nov 27;76(10):1444-7.</citation>
    <PMID>14657683</PMID>
  </reference>
  <reference>
    <citation>Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003 Jun;3(6):653-64. Review.</citation>
    <PMID>12780556</PMID>
  </reference>
  <reference>
    <citation>Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, Kamil E, Tyan D. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003 Aug 27;76(4):631-6.</citation>
    <PMID>12973100</PMID>
  </reference>
  <reference>
    <citation>Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant. 2005 Apr;9(2):155-61. Review.</citation>
    <PMID>15787786</PMID>
  </reference>
  <reference>
    <citation>Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, Leffell MS. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation. 2003 Nov 27;76(10):1519-25.</citation>
    <PMID>14657698</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2004</study_first_submitted>
  <study_first_submitted_qc>August 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2004</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Transplantation, Homologous</keyword>
  <keyword>HLA Antigens</keyword>
  <keyword>Autoantibodies</keyword>
  <keyword>Immunoglobulins, Intravenous</keyword>
  <keyword>Living Donors</keyword>
  <keyword>Dose-Response Relationship, Immunologic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>SDY356</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY356</doc_url>
      <doc_comment>ImmPort study identifier is SDY356</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY356</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY356</doc_url>
      <doc_comment>ImmPort study identifier is SDY356</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY356</doc_id>
      <doc_type>Study summary, -design, -demographics, -lab tests, -study files</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY356</doc_url>
      <doc_comment>ImmPort study identifier is SDY356</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

